We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Indoleamine 2,3-dioxygenase attenuates inhibitor development in gene-therapy-treated hemophilia A mice.
- Authors
Liu, L.; Liu, H.; Mah, C.; Fletcher, B. S.
- Abstract
A serious impediment to gene and protein replacement therapy in hemophilia A is the development of inhibitors. Mechanisms responsible for inhibitor development include T-cell-dependent adaptive immune responses and the CD28–B7 signaling pathway that eventually leads to the formation of antibodies directed against factor VIII (FVIII). Indoleamine 2,3-dioxygenase (IDO) is a potent immunosuppressive enzyme that can inhibit T-cell responses and induce T-cell apoptosis by regulation of tryptophan metabolism. Kynurenine, one of the metabolites of tryptophan, has been implicated as an immune modulator. Here we hypothesize that co-delivery of the genes for FVIII and IDO can attenuate inhibitor formation. Using transposon-based gene delivery, we observed long-term therapeutic FVIII expression and significantly reduced inhibitor titers when the genes were co-delivered. Co-expression of FVIII and IDO in the liver was associated with increased plasma kynurenine levels, an inhibition of T-cell infiltration and increased apoptosis of T cells within the liver. These experiments suggest that modulation of tryptophan catabolism through IDO expression provides a novel strategy to reduce inhibitor development in hemophilia gene/protein therapy.Gene Therapy (2009) 16, 724–733; doi:10.1038/gt.2009.13; published online 5 March 2009
- Subjects
HEMOPHILIA; T cells; APOPTOSIS; KYNURENINE; IMMUNOGLOBULINS
- Publication
Gene Therapy, 2009, Vol 16, Issue 6, p724
- ISSN
0969-7128
- Publication type
Article
- DOI
10.1038/gt.2009.13